Written by the Nuvirox Research Team
Key points
- GlyNAC is glycine plus N-acetylcysteine, supplied together as precursors to glutathione — the cell’s main internal antioxidant, which is depleted in older adults.
- In a randomised trial of 24 older adults, sixteen weeks of GlyNAC corrected glutathione deficiency and improved mitochondrial fuel oxidation, oxidative stress markers, inflammation, insulin resistance and gait speed. Young controls were unaffected.
- All of the human work comes from a single research group, with 12 people in the active arm. The results are striking and they have not been independently replicated. Both facts matter equally.
Short answer: GlyNAC has produced some of the most impressive results in the geroscience literature from some of the smallest trials in the geroscience literature. Twelve older adults on active treatment, one lab, no independent replication. The mechanism is sound, the effect sizes are remarkable, and the correct response to remarkable effect sizes from tiny single-centre studies is interest tempered by patience.
What is GlyNAC and why combine two amino acids?
Glutathione is a tripeptide of glutamate, cysteine and glycine, and it is the most abundant intracellular antioxidant in the body. Its concentration falls with age. The rate-limiting inputs for making it are cysteine and glycine — glutamate is rarely short.
N-acetylcysteine is a stable, absorbable cysteine donor. Glycine is supplied directly. The insight behind GlyNAC is that supplying only one of the two does not reliably restore glutathione, because the other becomes limiting. Supplying both together does.
The relevance to energy runs through mitochondria: oxidative stress damages mitochondrial function, and glutathione is the primary defence against it. We cover the general question in does oxidative stress actually make you tired and glutathione specifically in glutathione and fatigue.
What human studies actually show
The randomised trial. Twenty-four older adults and twelve young adults were studied. The older adults were randomised to GlyNAC (n = 12) or an isonitrogenous alanine placebo (n = 12) for sixteen weeks; the young adults received GlyNAC for two weeks as a comparison. Glutathione concentrations in muscle and red blood cells were lower at baseline in the older group and rose with treatment, while oxidative stress markers fell. Neither the young group nor the placebo-treated older group showed those changes.
Study snapshot
| Design | Randomised, placebo-controlled (isonitrogenous alanine comparator) |
| n | 24 older adults (12 active, 12 placebo) plus 12 young adults |
| Dose | Glycine 1.33 mmol/kg/day and N-acetylcysteine 0.83 mmol/kg/day |
| Duration | 16 weeks in older adults; 2 weeks in young controls |
| Reported outcomes | Restored mitochondrial fuel oxidation; gait speed increased 19%; reductions in oxidative stress (TBARS), inflammation (IL-6, TNF-alpha) and insulin resistance (HOMA-IR) |
| Source | Journals of Gerontology: Series A 2023;78(1):75–89 |
The earlier pilot. A 2021 open pilot from the same group reported improvements across glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength and cognition. Independent commentary at the time noted the breadth was itself striking — a single nutritional intervention appearing to correct components of several ageing hallmarks simultaneously — and called for a randomised trial, which is what followed.
Why the caution, if the results are that good?
The honest counterweight is structural rather than a specific flaw. Every human GlyNAC finding traces back to one research group at one institution, with twelve people in the active arm of the randomised trial. That is not a criticism of the investigators, who have been transparent about design and doses. It is a statement about how science establishes reliability.
- Effect sizes this large in samples this small are the classic setup for regression to the mean when larger trials follow. This pattern has repeated across nutrition and geroscience for decades.
- Multiple outcomes were reported without the multiplicity control that large confirmatory trials require, which raises the chance that some findings are noise.
- The doses are substantial and weight-based, not the fixed capsule doses most consumers would take. A 75 kg adult on the trial protocol is consuming several grams of each amino acid daily.
- No independent group has reproduced it. Until that happens, the correct epistemic state is genuine interest, not confidence.
What GlyNAC won’t do
It will not act quickly. The randomised trial ran sixteen weeks, and the young control group — who received two weeks — showed nothing, which is consistent with both a duration effect and with the intervention only doing something where a deficit exists.
It also will not help people who are not glutathione-depleted. The young adults in the trial were unaffected on every measure. That is arguably the most informative single result in the whole programme: this appears to be a correction of a deficit, not an enhancement.
Dose and realistic expectations
The trial used weight-based dosing: glycine at 1.33 mmol/kg/day and N-acetylcysteine at 0.83 mmol/kg/day. Most commercial GlyNAC products supply considerably less than the trial protocol for an average-sized adult, which means they are not testing the same thing the trial tested. Check the milligram amounts against your body weight before assuming equivalence.
A sixteen-week horizon is the evidence-based expectation. Gait speed and general functional capacity are more relevant things to watch than subjective energy, since those are what the trial actually measured. If you are approaching amino-acid interventions generally, our assessment of taurine and aging applies the same standard.
Frequently asked questions
Can I just take NAC on its own?
The GlyNAC rationale is specifically that supplying one precursor without the other leaves the second limiting. The trials tested the combination, so results from them do not transfer to NAC alone.
Is glycine alone enough?
Same logic in reverse. Glycine has its own literature, particularly around sleep, but the glutathione restoration data comes from the combination.
Why did the young adults show no benefit?
They were not glutathione-deficient at baseline. That is consistent with GlyNAC correcting a deficit rather than enhancing normal function — a useful and honest finding that limits who it plausibly helps.
How large were the reported effects?
Large. Gait speed rose 19%, and the trial reported substantial reductions in oxidative stress, IL-6, TNF-alpha and HOMA-IR. Effect sizes of that magnitude in a 12-person arm are exactly what independent replication exists to test.
Is it safe long term?
The randomised data covers sixteen weeks. Both compounds have long histories of use, but the specific combination at trial doses has not been characterised over years.
From Nuvirox
Why we formulated NAD+ Restore.
GlyNAC targets the antioxidant defence side of mitochondrial health. NAD+ Restore targets coenzyme availability. They are different bets on the same system, and we are explicit about which one we made.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
- 150 mg trans-resveratrol (Japanese Knotweed) + 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
- 10 mg galactomannans from fenugreek — to support absorption.
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
The bottom line
GlyNAC is the most interesting under-replicated finding in this whole category. A randomised, placebo-controlled trial in older adults reported restored mitochondrial fuel oxidation, a 19% gait speed improvement and large reductions in oxidative stress, inflammation and insulin resistance — with young controls showing nothing, which is exactly the pattern a genuine deficit correction should produce. It is also twelve people in one lab. If you try it, use the trial's weight-based doses rather than whatever a capsule contains, give it sixteen weeks, and hold the result loosely until somebody else finds the same thing.
References
- Kumar P, Liu C, Suliburk J, et al. Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: a randomized clinical trial. The Journals of Gerontology: Series A. 2023;78(1):75-89. PMID: 35975308. DOI: 10.1093/gerona/glac135.
- Kumar P, Liu C, Hsu JW, et al. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: results of a pilot clinical trial. Clinical and Translational Medicine. 2021;11(3):e372. PMCID: PMC8002905. DOI: 10.1002/ctm2.372.
- Singh P, Gollapalli K, Mangiola S, et al. Taurine deficiency as a driver of aging. Science. 2023;380(6649):eabn9257. PMID: 37289866. DOI: 10.1126/science.abn9257.
- Dunn J, Grider MH. Physiology, adenosine triphosphate. StatPearls. NCBI Bookshelf ID: NBK553175.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.